1. Мельниченко Г.А., Стилиди И.С., Алексеев Б.Я., Горбунова В.А., Бельцевич Д.Г., Райхман А.О., Кузнецов Н.С., Жуков Н.В., Бохян В.Ю. Федеральные клинические рекомендации по диагностике и лечению адренокортикального рака. Проблемы эндокринологии. 2014; 60(2): 51 - 67. doi: 10.14341/probl201460251-67

2. Lloyd RV, Osamura RY, G, Rosai J, eds. WHO Classification of Tumours of Endocrine Organs. Fourth Edition. Lyon: IARC; 2017

3. Селиванова Л.С., Рослякова А.А., Боголюбова А.В., Тертычный А.С., Бельцевич Д.Г., Абросимов А.Ю., Мельниченко Г.А. Молекулярно-генетические маркеры и критерии прогноза адренокортикального рака. Архив патологии. 2019; 81(5): 92 - 96. doi: 10.17116/patol20198105192

4. Else T. Association of Adrenocortical Carcinoma with Familial Cancer Susceptibility Syndromes. Mol Cell Endocrinol. 2012; 351(1): 66 - 70. doi: 10.1016/j.mce.2011.12.008

5. Schteingart DE, Doherty GM, Gauger PG, et al. Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer. 2005; 12: 667. doi: 10.1677/erc.1.01029

6. Министерство здравоохранения Российской Федерации. Перечень редких (орфанных) заболеваний. https://www.rosminzdrav.ru/documents/8048 [ссылка активна на 27.10.2019]

7. Adrenal Cortical Carcinoma. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017

8. Fassnacht M, Dekkers O, Else T, Baudin E, Berruti A, de Krijger RR, Haak HR, Mihai R, Assie G, Terzolo M. European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. EJE. 2018; 179(4): G1 - G46. doi: 10.1530/EJE-18-0608.

9. Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res ClinEndocrinolMetab. 2009; 23(2): 273 - 89. doi: 10.1016/j.beem.2008.10.008

10. Chuang B, Fassnacht M. Adrenocortical carcinoma: clinical update. J ClinEndocrinolMetab. 2006; 91(6): 2027 - 37. doi: 10.1210/jc.2005-2639

11. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg. 1997; 132(2): 914 - 919. doi: 10.1001/archsurg.1997.01430320116020

12. Cawood TJ, Hunt PJ, O'Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol. 2009; 161(4): 513 - 27. doi: 10.1530/EJE-09-0234.

13. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016; 175(2): G1 - G34. doi: 10.1530/EJE-16-0467.

14. Селиванова Л.С., Рослякова А.А., Коваленко Ю.А., Боголюбова А.В., Тертычный А.С., Бельцевич Д.Г., Абросимов А.Ю., Мельниченко Г.А. Современные критерии диагностики адренокортикального рака. Архив патологии. 2019; 81(3): 66 - 73. https://doi.org/10.17116/patol20198103166

15. Бельцевич Д.Г., Кузнецов Н.С., Солдатова Т.В., Ванушко В.Э. Инциденталома надпочечников. Эндокринная хирургия. 2009; 3(1): 19 - 23.

16. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. 2006; 29(4): 298 - 302. doi: 10.1007/BF03344099

17. Young WFJr. The Incidentally Discovered Adrenal Mass. N Engl J Med. 2007; 356: 601 - 10. doi: 10.1056/NEJMcp065470

18. Libe R, Dall'Asta C, Barbetta L et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur J Endocrinol. 2002; 147: 489 - 494. doi: 10.1530/eje.0.1470489

19. Terzolo M, Reimondo G, Bovio S, Angeli A Subclinical Cushing's syndrome. Pituitary. 2004; 7(4): 217 - 223. doi: 10.1007/s11102-005-4024-6

20. Kirkby-Bott J, Brunaud L, Mathonet M, Hamoir E, Kraimps JL, C, Amar L, Rault A, Henry JF, Carnaille B. Ectopic hormone-secreting pheochromocytoma: a francophone observational study. World J Surg. 2012; 36(6): 1382 - 8. doi: 10.1007/s00268-012-1488-1.

21. Li XG, Zhang DX, Li X, Cui XG, Xu DF, Li Y, Gao Y, Yin L, Ren JZ Adrenocorticotropic hormone-producing pheochromocytoma: a case report and review of the literature. Chin Med J (Engl). 2012; 125(6): 1193 - 1196. doi: 10.3760/cma.j.issn.0366-6999.2012.06.042

22. Cohade C, Broussaud S, Louiset E, Bennet A, Huyghe E, Caron P. Ectopic Cushing"s syndrome due to a pheochromocytoma: a new case in the post-partum and review of literature. Gynecol Endocrinol. 2009; 25(9): 624 - 627. doi: 10.1080/09513590903015411

23. Gardet V et al. Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens. 2001; 19(6): 1029 - 1035. 10.1097/00004872-200106000-00006

24. Nieman LK, Biller BMK, Findling JW et al. The diagnosis of Cushing's syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008; 93(5): 1526 - 40. doi: 10.1210/jc.2008-0125.

25. Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing"s states. Endocr Rev. 1998; 19(5): 647 - 672. doi: 10.1210/edrv.19.5.0346

26. Pecori Giraldi F, Ambrogio AG, De Martin M, et al. Specificity of first-line tests for the diagnosis of Cushing's syndrome: assessment in a large series. J Clin Endocrinol Metab. 2007; 92(11): 4123 - 9. doi: 10.1210/jc.2007-0596

27. Tsagarakis S, Vassiliadi D, Thalassinos N. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J Endocrinol Invest. 2006; 29(5): 471 - 82. doi: 10.1007/BF03344133

28. Mitchell IC, Auchus RJ, Juneja K, et al. "Subclinical Cushing's syndrome" is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007; 142(6): 900 - 905. doi: 10.1016/j.surg.2007.10.001

29. Barzon L, Fallo F, Sonino N, Boscaro M. Development of overt Cushing's syndrome in patients with adrenal incidentaloma. Eur J Endocrinol. 2002; 146(1): 61 - 66. doi: 0.1530/eje.0.1460061

30. Reincke M. Subclinical Cushing's syndrome. Endocrinol Metab Clin North Am. 2000; 29(1): 43 - 56. doi: 10.1016/S0889-8529(05)70115-8

31. Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 2007; 92: 4069 - 4079. doi: 10.1210/jc.2007-1720

32. Williams DT, Dann S, Wheeler MH. Phaeochromocytoma - views on current management. Eur J Surg Oncol. 2003; 29(6): 483 - 490

33. Kinney M, Narr BJ, Warner MA. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2002; 16: 359 - 369. doi: 10.1053/jcan.2002.124150

34. Pacak K et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001; 134(4): 315 - 329. doi: 10.7326/0003-4819-134-4-200102200-00016

35. Дедов И.И., Бельцевич Д.Г., Кузнецов Н.С., Мельниченко Г.А. Феохромоцитома. Москва: Практ. медицина; 2005; 47 - 70.

36. An Endocrine Society Clinical Practice Guidelines. Case Detection, Diagnosis, and Treatment of Patients with Primary Aldosteronism. J Clin Endocrinol Metab. 2008; 93(9): 3266 - 3281.

37. Мельниченко Г.А., Платонова Н.М., Бельцевич Д.Г. и др. Первичный гиперальдостеронизм: диагностика и лечение. Новый взгляд на проблему. По материалам Проекта клинических рекомендаций Российской ассоциации эндокринологов по диагностике и лечению первичного гиперальдостеронизма. Consilium Medicum. 2017; 19(4): 75 - 85.

38. Mantero F, Terzolo M, Arnaldi G, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85(2): 637 - 644.

39. Angeli A, Osella G, Ali A, Terzolo M. Adrenal incidentaloma: an overview of clinical and epidemiological data from the National Italian Study Group. Horm Res. 1997; 47: 279 - 283.

40. Metser U, Miller E, Lerman H et al. 18F-FDG PET/CT in the Evaluation of Adrenal Masses. J Nucl Med. 2006; 47(1): 32 - 37.

41. M. Blake, P. Prakash, C. Cronin. PET/CT for Adrenal Assessment Am J Roentgenology. 2010; 195(2): 195.

42. Mackie GC, Shulkin BL, Ribeiro RC, et al. Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab. 2006; 91: 2665.

43. Leboulleux S, Dromain C, Bonniaud G et al. Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab. 2006; 91: 920.

44. Deandreis D, Leboulleux S, Caramella C, et al. FDG PET in the management of patients with adrenal masses and adrenocortical carcinoma. Horm Cancer. 2011; 2: 354.

45. Welch TJ, Sheedy PF II, Stephens DH et al. Percutaneous adrenal biopsy: review of a 10-year experience. Radiology. 1994; 193: 341 - 344

46. Pacak K, Eisenhofer G, Ahlman H et al. Pheochromocytoma: recommendations for clinical practice from the First International Symposium. Nat Clin Pract Endocrinol Metab. 2007; 3: 92 - 102

47. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001; 25: 914 - 926

48. Ng L, Libertino JM. Adrenocortical carcinoma: diagnosis, evaluation and treatment. J Urol. 2003; 169: 5 - 11

49. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984; 8(3): 163 - 169.

50. Lau SK, Weiss LM. The Weiss system for evaluating adrenocortical neoplasms: 25 years later. Hum Pathol. 2009; 40(6): 757 - 768.

51. Van Slooten H, Schaberg A, Smeenk D, Moolenar AJ. Morphologic characteristics of benign and malignant adrenocortical tumors. Cancer. 1985 Feb 15; 55(4): 766 - 773.

52. Blanes A et al. Histologic criteria for adrenocortical proliferative lesions: value of mitotic figure variability. Am J Clin Pathol. 2007; 127(3): 398 - 408.

53. Филиппова О.В. Адренокортикальный рак: клинические проявления и морфологическая диагностика/Филиппова О.В., Хмельницкая Н.М. // Медицинский альманах. 2011; 5: 113 - 116.

54. B, Khorram-Manesh A, Jansson S, et al. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocr Relat Cancer. 2010; 17: 265.

55. Филимонюк А.В., Харченко Н.В., Леонов Б.И., Смирнова Е.А., Антонов А.К., Смелкова Н.И. Непосредственные и отдаленные результаты хирургического лечения больных адренокортикальным раком. Вестник новых медицинских технологий (электронное издание). 2013; 1 [Электронный ресурс].

56. Casola G, Nicolet V, van Sonnenberg E et al. Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal biopsy. Radiology. 1986; 159: 733 - 735.

57. Reibetanz J, Jurowich C, Erdogan I et al. Impact of lymphadenectomy on the oncologic outcome of patients with adrenocortical carcinoma. Ann Surg. 2012; 255: 363

58. Gaujoux S, Brennan MF. Recommendation for standardized surgical management of primary adrenocortical carcinoma. Surgery. 2012 152(1): 123 - 32

59. Leboulleux S, Deandreis D, Ghuzlan A Al et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal сarcinomatosis? Eur J Endocrinol. 2010; 162: 1147 - 1153

60. Miller BS, Gauger PG, Hammer GD et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch Surg. 2010; 395: 955/

61. Shen WT, Sturgeon C, Duh QY. From incidentaloma to adrenocortical carcinoma: the surgical management of adrenal tumors. J Surg Oncol. 2005; 89(3): 186 - 92. doi: 10.1002/jso.20180

62. Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999; 6(8): 719 - 726

63. Icard P, Chapuis Y, Andreassian B, et al. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery. 1992; 112(6): 972 - 979.

64. Bellantone R, Ferrante A, Boscherini M, et al.: Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma. Surgery. 1997, 122: 1212 - 1218.

65. Porpiglia F, Fiori C, Scarpa RM et al. The role of surgery in the management of recurrent adrenocortical carcinoma: results of a retrospective study. Eur Urol Suppl. 2009; 8(4): 305.

66. Brix D, Allolio B, Fenske W et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010; 58: 609.

67. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6: 386 - 394.

68. Schteingart DE. Conventional and novel strategies in the treatment of adrenocortical cancer. Braz J Med Biol Res. 2000; 33: 1197 - 1200

69. Hague RV, May W, Cullen DR. Hepatic microsomal enzyme induction and adrenal crisis due to o,p_DDD therapy for metastatic adrenocortical carcinoma. Clin Endocrinol (Oxf). 1989; 31: 51 - 57

70. Министерство здравоохранения Российской Федерации. Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения. https://www.rosminzdrav.ru/ministry/61/10/stranitsa-858/perechen-zhiznenno-neobhodimyh-i-vazhneyshih-lekarstvennyh-preparatov-dlya-meditsinskogo-primeneniya-na-2018-god [ссылка активна на 27.10.2019

71. Lim MC, Tan YO, Chong PY, Cheah JS. Treatment of adrenal cortical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore. 1990.

72. Decker RA, Kuehner ME. Adrenocortical carcinoma. Am Surg. 1991; 57: 502 - 513.

73. Terzolo, M. Adjuvant mitotane treatment for adrenocortical carcinoma/M. Terzolo Angeli A, Fassnacht M et al. // N. Engl. J. Med. - 2007. - Vol. 356, N 23. - P. 2372 - 2380.

74. Ilias I, Alevizaki M, Philippou G, Anastasiou E, Souvatzoglou A. Sustained remission of metastatic adrenal carcinoma during long-term administration of low-dose mitotane. J Endocrinol Invest. 2001; 24: 532 - 535.

75. Allolio B, Hahner S, Weismann D, Fassnacht M. Management of adrenocortical carcinoma. Clin Endocrinol (Oxf). 2004; 60: 273 - 287. 19: 540 - 544.

76. Hahner S, Fassnacht M. Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs. 2005; 6: 386 - 394

77. Van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984; 20: 47 - 53.

78. Haak HR, Hermans J, van de Velde CJ et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer. 1994; 69: 947 - 951.

79. Baudin E, Pellegriti G, Bonnay M et al. Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p_DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer. 2001; 92: 1385 - 1392.

80. Heilmann P, Wagner P, Nawroth PP, Ziegler R [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p-DDD blood levels]. Med Klin. 2001; 96: 371 - 377

81. Becker D, Schumacher OP. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med. 1975; 82: 677 - 679.

82. Boven E, Vermorken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o,p-DDD. Case report and literature review. Cancer. 1984; 53: 26 - 29.

83. Krzisnik C, Petric G, Jereb B. Complete response of metastatic adrenal cortical carcinoma to o,p-DDD in a child. Pediatr Hematol Oncol. 1988; 5: 65 - 69.

84. Terzolo M, Daffara F, Ardito A, Zaggia B, Basile V, Ferrari L, Berruti A. Management of adrenal cancer: a 2013 update. Endocrinol Invest. 2014; 37(3): 207 - 17. doi: 10.1007/s40618-013-0049

85. Huang H, Fojo T. Adjuvant mitotane for adrenocortical cancer - a recurring controversy. Journal of Clinical Endocrinology and Metabolism. 2008; 93(10): 3730 - 3732. doi: 10.1210/jc.2008-0579

86. Terzolo M, Fassnacht M, Ciccone G, Allolio B, Berruti A. Adjuvant Mitotane for Adrenocortical Cancer - Working through Uncertainty. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(6): 1879 - 1880. doi: 10.1210/jc.2009-0120

87. Kroiss M, Quinkler M, Lutz WK, Allolio B, Fassnacht M. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology; 2011; 75: 585 - 591. doi: 10.1111/j.1365-2265.2011.04214.x

88. Cordon-Cardo C, O"Brien JP, Boccia J et al. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem. 1990; 38: 1277 - 1287.

89. Flynn SD, Murren JR, Kirby WM et al. P-glycoprotein expression and multidrug resistance in adrenocortical carcinoma. Surgery. 1992; 112: 981 - 986.

90. Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst. 1989; 81: 116 - 124.

91. Fridborg H, Larsson R, Juhlin C, Rastad J, Akerstrom G, Backlin K, Nygren P P-glycoprotein expression and activity of resistance modifying agents in primary cultures of human renal and adrenocortical carcinoma cells. An-ticancer Res. 1994; 14: 1009 - 1016.

92. Haak HR, van Seters AP, Moolenaar AJ, Fleuren GJ Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer. Eur J Cancer. 1993; 29A: 1036 - 1038.

93. Fassnacht M, Terzolo M, Allolio B et al. Combination chemotherapy in advanced adrenocortical carcinoma. FIRM-ACT Study GroupN Engl J Med. 2012; 366(23): 2189.

94. Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010; 17(2): 445 - 53.

95. Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism. 2017; 102: 1358 - 1365. doi: 10.1210/jc.2016-2894

96. Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism. 2006; 91: 4501 - 4504.

97. Habra MA, Ejaz S, Feng L, et al. A Retrospective Cohort Analysis of the Efficacy of Adjuvant Radiotherapy after Primary Surgical Resection in Patients with Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism. 2013; 98: 192 - 197. doi: 10.1210/jc.2012-2367)

98. Sabolch A, Else T, Griffth KA, et al. Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma. International Journal of Radiation Oncology, Biology, Physics. 2015; 92: 252 - 259. doi: 10.1016/j.ijrobp.2015.01.007

99. Cerquetti L, Bucci B, Marchese R, et al. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines. Endocrine-Related Cancer. 2008; 15: 623 - 634. doi: 10.1677/erc.1.1315

100. Cerquetti L, Sampaoli C, Amendola D, et al. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation. International Journal of Oncology. 2010; 37: 493 - 501.

101. Abiven-Lepage G, Coste J, Tissier F, et al. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. European Journal of Endocrinology 2010; 163: 793 - 800. doi: 10.1530/EJE-10-0412)

102. Sirianni R, Zolea F, Chimento A, et al. Targeting estrogen receptor-alpha reduces adrenocortical cancer (ACC) cell growth in vitro and in vivo: potential therapeutic role of selective estrogen receptor modulators (SERMs) for ACC treatment. Journal of Clinical Endocrinology and Metabolism. 2012; 97: E2238 - E2250. doi: 10.1210/jc.2012-2374

103. Icard P, Goudet P, Charpenay C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons Study Group. World J Surg. 2001; 25: 891 - 897.

104. Crucitti F, Bellantone R, Ferrante A, et al. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery. 1996; 119: 161 - 170.

105. Pommier RF, Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992; 112: 963 - 970; discussion, 970 - 971.

106. Soreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970 - 1984. World J Surg. 1992; 16: 663 - 667; discussion, 668.

107. Vassilopoulou-Sellin R, Schultz PN. Adrenocortical carcinoma. Clinical outcome at the end of the 20th century. Cancer. 2001; 92: 1113 - 1121.

108. Johanssen S, Hahner S, Saeger W, et al. Deficits in the management of patients with adrenocortical carcinoma in Germany. Deutsches Arzteblatt International. 2010; 107: U885 - U889.

109. Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113: 3130 - 3136. (doi: 10.1002/cncr.23886

110. Libe R, Borget I, Ronchi CL, et al. Prognostic factors in stage III - IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology.

111. Miller BS, Gauger PG, Hammer GD, Giordano TJ & Doherty GM. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Archives of Surgery 2010 395 955 - 961. (https://doi.org/10.1007/s00423-010-0698-y)

112. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. American Journal of Surgical Pathology. 1989; 13: 202 - 206. doi: 10.1097/00000478-198903000-00004 Morimoto R, Satoh F, Murakami O, et al. Immunohistochemistry of aproliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas. Endocrine Journal. 2008; 55: 49 - 55. doi: org/10.1507/endocrj.K07-079

113. Asare EA, Wang TS, Winchester DP, et al. A novel staging system for adrenocortical carcinoma better predicts survival in patients with stage I/II disease. Surgery. 2014; 156: 1378 - 1386. doi: 10.1016/j.surg.2014.08.018

114. Abiven-Lepage G, Coste J, Tissier F, et al. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. European Journal of Endocrinology. 2010; 163: 793 - 800. doi: 10.1530/EJE-10-0412

115. De Corbiere P, Ritzel K, Cazabat L, et al. Pregnancy in women previously treated for an adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism. 2015; 100: 4604 - 4611. doi: 10.1210/jc.2015-2341

116. Всероссийское общество редких (орфанных) заболеваний (http://akr.rare-diseases.ru/)

117. Pennanen, M. Helsinki score - a novel model for prediction of metastases in adrenocortical carcinomas / M. Pennanen, I. Heiskanen, T. Sane et al. // Human Pathology. - 2015. - Vol. 46, N 3. - P. 404 - 410.

118. Hough, A.J. Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data / A.J. Hough, J.W. Hollifield, D.L. Page et al. // Am J Clin Pathol. - 1979. - Vol. 72. - P. 390 - 399.

119. Aubert, S. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors / S. Aubert, A. Wacrenier, X. Leroy et al. // Am. J. Surg. Pathol. - 2002. - Vol. 26, N 12. - P. 1612 - 1619.

120. Papotti, M. The Weiss score and beyond - histopathology for adrenocortical carcinoma / M. Papotti, R. Lib, E. Duregon et al. // Horm. Cancer. - 2011. - Vol. 2, N 6. - P. 333 - 340.

121. Volante, M. Pathological and molecular features of adrenocortical carcinoma: an update / M. Volante, C. Buttigliero, E. Greco et al. // J. Clin. Pathol. - 2008. - Vol. 61. - N 7. - P. 787 - 793.

122. Sasano, H. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma / H. Sasano, T. Suzuki, T. Moriya // Endocr. Pathol. - 2006. - Vol. 17, N 4. - P. 345 - 354.

123. Beuschlein, F. Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection / F. Beuschlein, J. Weigel, W. Saeger et al. // J Clin Endocrinol Metab, 2015. - Vol. 100. - P. 841 - 849.

124. Papathomas, T. An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma / T. Papathomas, E. Pucci, T. Giordano et al. // Am J Surg Pathol. - 2016. - Vol. 40. - P. 569 - 576.

125. Adrenal Cortical Carcinoma. In: Brierley JD, Gospodarowicz MK, Wittekind C (eds). TNM Classification of Malignant Tumours (8th edition). Oxford, UK: Wiley-Blackwell, 2017.

126. Libe, R. Prognostic factors in stage III - IV adrenocortical cancinoma (ACC): an European Network for the study of adrenal tumor (ENSAT) study / R. Libe, I. Borget, L. Ronchi // Annals of Oncology. - 2015. - Vol. 26. - P. 2119 - 2125.

127. Бохян В.Ю., Павловская А.И., Губина Г.И., Стилиди И.С. Клиническая оценка гистологических систем диагностики адренокортикальных опухолей // Архив патологии. - 2015. - N 3. - Т. 77. - Стр. 17 - 22.

128. Стилиди И.С., В.Ю. Бохян, И.Е. Карманов. Поражение нижней полой вены при адренокортикальном раке: результаты хирургического лечения // Анналы хирургии. - 2016. N 4. - Т. 21. - Стр. 248 - 256.

129. Fassnacht M, Kenn W & Allolio B. Adrenal tumors: How to establish malignancy? J Endocrinol Invest 2270 2004 27 387 - 399.

130. Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R & Welt CK. Diagnosis and 2279 treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin 2280 Endocrinol Metab 2013 98 4565 - 4592.

131. Chortis V, Taylor AE, Schneider P, Tomlinson JW, Hughes BA, O'Neil DM, R, Allolio B, Bertagna X, Bertherat J, et al. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5-reductase, explaining the need for personalized glucocorticoid and androgen replacement. Journal of Clinical Endocrinology and Metabolism 2013 98 161 - 171. (https://doi.org/10.1210/jc.2012-2851)]

132. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, et al.: Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatr Blood Cancer 45 (3): 265 - 73, 2005.

133. Zancanella P, Pianovski MA, Oliveira BH, et al.: Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. J Pediatr Hematol Oncol 28 (8): 513 - 24, 2006.

134. Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998; 83: 2194 - 2200